✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glenmark Pharmaceuticals Ltd.

GLENMARK

Market Cap
₹60,763 Cr.
P/E
44.62

Glenmark Pharmaceuticals Ltd.

  • Glenmark Pharma.
  • Alkem Laboratories
  • Abbott India
  • TJI Pharma

FAQs on Glenmark Pharmaceuticals Ltd. Shareprice

Glenmark Pharma. has given better returns compared to its competitors.
Glenmark Pharma. has grown at ~27.22% over the last 5yrs while peers have grown at a median rate of 10.83%

Glenmark Pharma. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Glenmark Pharma. is 44.62, while 3 year average PE is 25.95.
Also latest EV/EBITDA of Glenmark Pharma. is 13.03 while 3yr average is 15.44.

View FAQ's On Business

Growth Table

  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Balance Sheet

  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Cash Flow

  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Quarterly Results

  • Glenmark Pharmaceuticals Ltd.
  • Alkem Laboratories
  • Abbott India

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Glenmark Pharmaceuticals Ltd. Financials

Balance sheet of Glenmark Pharma. is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Glenmark Pharma. is increasing.
Latest net debt of Glenmark Pharma. is -₹1,176.26 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹1,215.19 Crs.

Yes, profit is increasing.
The profit of Glenmark Pharma. is ₹1,362 Crs for TTM, ₹1,047 Crs for Mar 2025 and -₹1,501.67 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Glenmark Pharma. latest dividend payout ratio is 6.74% and 3yr average dividend payout ratio is 15.23%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech